Lixte Biotechnology Holdings, INC. (LIXT) — SEC Filings

Overview

Lixte Biotechnology Holdings, INC. (LIXT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 31, 2025: Lixte Biotechnology Holdings, Inc. filed an 8-K on December 31, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and financial statements. The filing details events that occurred on December 30, 2025, with the company's principal executive offices located

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 6 bearish, 41 neutral, 3 mixed. The dominant filing sentiment for Lixte Biotechnology Holdings, INC. is neutral.

Filing Type Overview

Lixte Biotechnology Holdings, INC. (LIXT) has filed 35 8-K, 5 10-Q, 1 DEFA14A, 2 DEF 14A, 4 S-1/A, 2 S-1, 1 10-K with the SEC between Jul 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• Lixte Biotechnology Files 8-K on Agreements & Equity — 8-K · Dec 31, 2025 Risk: medium
  Lixte Biotechnology Holdings, Inc. filed an 8-K on December 31, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and
• Lixte Biotechnology Enters Material Definitive Agreement — 8-K · Dec 23, 2025 Risk: medium
  Lixte Biotechnology Holdings, Inc. announced on December 17, 2025, that it entered into a material definitive agreement. The company, incorporated in Delaware w
• Lixte Biotech Enters and Terminates Agreements — 8-K · Dec 22, 2025 Risk: medium
  Lixte Biotechnology Holdings, Inc. reported on December 16, 2025, the entry into and termination of material definitive agreements. The company, incorporated in
• Lixte Biotechnology Files 8-K on Shareholder Vote Matters — 8-K · Dec 11, 2025 Risk: low
  Lixte Biotechnology Holdings, Inc. filed an 8-K on December 11, 2025, reporting on events that occurred on December 8, 2025. The filing indicates a submission o
• 8-K Filing — 8-K · Nov 25, 2025
• Lixte Biotech's Losses Mount Amidst Strategic Shift & Nasdaq Scrutiny — 10-Q · Nov 12, 2025 Risk: high
  LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported a net loss of $3,465,626 for the nine months ended September 30, 2025, an increase from a net loss of $2,968,271 in
• Lixte Biotechnology Files Proxy Materials — DEFA14A · Oct 28, 2025 Risk: low
  Lixte Biotechnology Holdings, Inc. (LIXT) filed a Definitive Additional Materials (DEFA14A) on October 28, 2025. The filing concerns proxy materials, indicating
• Lixte Seeks Shareholder Approval for Expanded Stock Plan, Director Slate — DEF 14A · Oct 27, 2025 Risk: medium
  Lixte Biotechnology Holdings, Inc. (LIXT) is holding its 2025 Annual Meeting of Stockholders on December 8, 2025, to address several key proposals. The company
• Lixte Biotechnology Files 8-K — 8-K · Sep 11, 2025 Risk: low
  Lixte Biotechnology Holdings, Inc. filed an 8-K on September 11, 2025, reporting an event that occurred on September 10, 2025. The filing is a current report pu
• Lixte Biotech Appoints New Chief Medical Officer — 8-K · Sep 4, 2025 Risk: medium
  Lixte Biotechnology Holdings, Inc. announced on September 3, 2025, the appointment of Dr. John B. "Jack" Greene as Chief Medical Officer. Dr. Greene, previously
• Lixte Biotechnology Files 8-K — 8-K · Aug 19, 2025 Risk: low
  Lixte Biotechnology Holdings, Inc. filed an 8-K on August 18, 2025, reporting other events and financial statements. The company, incorporated in Delaware, has
• Lixte Biotechnology Holdings Files 8-K — 8-K · Aug 14, 2025 Risk: low
  Lixte Biotechnology Holdings, Inc. filed an 8-K on August 14, 2025, reporting events as of August 13, 2025. The filing indicates the company's principal executi
• LIXTE Biotech Remains Pre-Revenue, Faces Funding Hurdles — 10-Q · Aug 7, 2025 Risk: high
  LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-revenue stage as a pharmaceutic
• Lixte Biotech Appoints New Chief Medical Officer — 8-K · Jul 21, 2025 Risk: medium
  Lixte Biotechnology Holdings, Inc. announced on July 21, 2025, that its Board of Directors appointed Dr. John B. McCarthy as Chief Medical Officer, effective Ju
• Lixte Biotechnology Files 8-K on Stock and Warrants — 8-K · Jul 16, 2025 Risk: low
  Lixte Biotechnology Holdings, Inc. filed an 8-K on July 16, 2025, reporting an event that occurred on July 15, 2025. The filing indicates changes related to its
• Lixte Biotechnology Raises $1.5M in Preferred Stock Sale — 8-K · Jul 11, 2025 Risk: medium
  Lixte Biotechnology Holdings, Inc. announced on July 11, 2025, that it entered into a securities purchase agreement on July 9, 2025. This agreement involves the
• LIXTE Amends S-1/A for Public Offering, Signals Capital Raise — S-1/A · Jul 10, 2025 Risk: medium
  LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) filed an S-1/A on July 10, 2025, indicating an amendment to its registration statement for a proposed public offering.
• Lixte Biotechnology Files 8-K for Material Agreement — 8-K · Jul 8, 2025 Risk: medium
  On July 8, 2025, Lixte Biotechnology Holdings, Inc. filed an 8-K report detailing a material definitive agreement entered into on July 3, 2025. The filing also
• Lixte Biotechnology Announces Material Definitive Agreement — 8-K · Jul 3, 2025 Risk: medium
  Lixte Biotechnology Holdings, Inc. announced on July 2, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sa
• LIXTE Amends S-1 for Public Offering, Updates Executive Info — S-1/A · Jun 24, 2025 Risk: high
  LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) filed an S-1/A on June 24, 2025, as an amendment to its initial S-1 registration statement, indicating a proposed publ
• LIXTE Biotech Files S-1 for Public Offering, Signaling Capital Raise — S-1 · Jun 18, 2025 Risk: high
  LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) filed an S-1 registration statement on June 18, 2025, indicating a proposed public offering of securities. The company
• Lixte Biotech Announces Material Agreement, Officer Changes — 8-K · Jun 17, 2025 Risk: medium
  Lixte Biotechnology Holdings, Inc. announced on June 16, 2025, the entry into a material definitive agreement. The company also reported the departure of direct
• Lixte Biotechnology Changes Principal Executive Offices — 8-K · May 20, 2025 Risk: low
  On May 16, 2025, LIXTE BIOTECHNOLOGY HOLDINGS, INC. filed an 8-K report detailing an event. The filing indicates a change in the company's principal executive o
• Lixte Biotechnology Holdings Q1 2025 10-Q Filing — 10-Q · May 12, 2025 Risk: medium
  LIXTE BIOTECHNOLOGY HOLDINGS, INC. filed its quarterly report for the period ending March 31, 2025. The company, previously known as SRKP 7 INC, is involved in
• Lixte Biotechnology Faces Delisting Notice — 8-K · Apr 18, 2025 Risk: high
  Lixte Biotechnology Holdings, Inc. filed an 8-K on April 17, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company i
• Lixte Biotechnology Holdings Files S-1/A Amendment — S-1/A · Apr 9, 2025 Risk: medium
  Lixte Biotechnology Holdings, Inc. filed an S-1/A amendment on April 9, 2025, for a registration statement. The company, previously known as SRKP 7 INC, is inco
• Lixte Biotechnology Files S-1 Registration — S-1 · Apr 4, 2025 Risk: medium
  Lixte Biotechnology Holdings, Inc. filed an S-1 registration statement on April 4, 2025, to register an unspecified number of securities. The company, incorpora
• Lixte Biotechnology Files 8-K — 8-K · Mar 31, 2025 Risk: low
  Lixte Biotechnology Holdings, Inc. filed an 8-K on March 31, 2025, reporting on other events and financial statements. The company, incorporated in Delaware wit
• Lixte Biotechnology Holdings Files 8-K — 8-K · Mar 27, 2025 Risk: low
  Lixte Biotechnology Holdings, Inc. filed an 8-K on March 27, 2025, reporting other events and financial statements. The company, incorporated in Delaware with i
• Lixte Biotechnology Files 2024 10-K — 10-K · Mar 24, 2025 Risk: medium
  Lixte Biotechnology Holdings, Inc. filed its 2024 10-K on March 24, 2025, reporting on its fiscal year ending December 31, 2024. The company, incorporated in De
• Lixte Biotechnology Enters Material Definitive Agreement — 8-K · Mar 14, 2025 Risk: medium
  Lixte Biotechnology Holdings, Inc. entered into a material definitive agreement on March 11, 2025. The company, incorporated in Delaware with its principal exec
• Lixte Biotechnology Holdings, Inc. Files 8-K — 8-K · Mar 11, 2025 Risk: low
  Lixte Biotechnology Holdings, Inc. filed an 8-K on March 11, 2025, reporting on events that occurred on March 10, 2025. The filing indicates the company's princ
• LIXTE BIOTECHNOLOGY FILES 8-K REPORT — 8-K · Feb 25, 2025 Risk: low
  On February 25, 2025, LIXTE BIOTECHNOLOGY HOLDINGS, INC. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibit
• Lixte Biotechnology Faces Delisting Concerns — 8-K · Feb 21, 2025 Risk: high
  Lixte Biotechnology Holdings, Inc. filed an 8-K on February 21, 2025, reporting a notice of delisting or failure to meet continued listing standards as of Febru
• Lixte Biotechnology Files 8-K on Definitive Agreement & Equity Sales — 8-K · Feb 13, 2025 Risk: medium
  Lixte Biotechnology Holdings, Inc. announced on February 11, 2025, the entry into a material definitive agreement and unregistered sales of equity securities. T
• Lixte Biotechnology Files 8-K on Material Agreement — 8-K · Jan 6, 2025 Risk: medium
  On January 6, 2025, Lixte Biotechnology Holdings, Inc. filed an 8-K report detailing a material definitive agreement. The filing indicates the company's princip
• Lixte Biotechnology Changes HQ, Reports Officer/Director Updates — 8-K · Dec 27, 2024 Risk: medium
  Lixte Biotechnology Holdings, Inc. announced on December 23, 2024, a change in its principal executive offices to 680 East Colorado Boulevard, Suite 180, Pasade
• Lixte Biotechnology Holdings Files 8-K on Shareholder Vote Matters — 8-K · Dec 20, 2024 Risk: low
  Lixte Biotechnology Holdings, Inc. filed an 8-K on December 20, 2024, reporting on a submission of matters to a vote of security holders that occurred on Decemb
• Lixte Biotechnology Enters Material Definitive Agreement — 8-K · Dec 2, 2024 Risk: medium
  Lixte Biotechnology Holdings, Inc. entered into a material definitive agreement on November 29, 2024. The filing does not specify the nature of the agreement or
• LIXTE BIOTECHNOLOGY 10-Q Filing for Q3 2024 — 10-Q · Nov 12, 2024 Risk: medium
  LIXTE BIOTECHNOLOGY HOLDINGS, INC. filed its 10-Q for the period ending September 30, 2024. The filing covers the third quarter and the first nine months of the
• Lixte Biotechnology Holdings DEF 14A Filing — DEF 14A · Nov 5, 2024 Risk: low
  LIXTE BIOTECHNOLOGY HOLDINGS, INC. filed a Definitive Proxy Statement (DEF 14A) on November 5, 2024. This filing is related to the company's annual meeting and
• Lixte Biotechnology Files S-1/A Amendment — S-1/A · Nov 1, 2024 Risk: medium
  Lixte Biotechnology Holdings, Inc. filed an S-1/A amendment on November 1, 2024, to its registration statement. The company, incorporated in Delaware, is involv
• Lixte Biotechnology Faces Delisting Concerns — 8-K · Oct 23, 2024 Risk: high
  Lixte Biotechnology Holdings, Inc. filed an 8-K on October 23, 2024, reporting a notice of delisting or failure to meet continued listing standards as of Octobe
• Lixte Biotechnology Files 8-K — 8-K · Sep 5, 2024 Risk: low
  Lixte Biotechnology Holdings, Inc. filed an 8-K on September 4, 2024, reporting an event related to its financial statements and exhibits. The filing does not c
• Lixte Biotechnology Files 8-K — 8-K · Aug 26, 2024 Risk: low
  Lixte Biotechnology Holdings, Inc. filed an 8-K on August 26, 2024, reporting other events and financial statements. The company, incorporated in Delaware, is l
• Lixte Biotechnology Faces Delisting Notice — 8-K · Aug 23, 2024 Risk: high
  Lixte Biotechnology Holdings, Inc. filed an 8-K on August 23, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard,
• Lixte Biotech Raises $1.9M via Stock and Warrant Sale — 8-K · Aug 19, 2024 Risk: medium
  Lixte Biotechnology Holdings, Inc. announced on August 15, 2024, that it has entered into a securities purchase agreement with an institutional investor. The ag
• Lixte Biotechnology Holdings Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
  Lixte Biotechnology Holdings, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the
• Lixte Biotechnology Enters Material Definitive Agreement — 8-K · Jul 12, 2024 Risk: medium
  Lixte Biotechnology Holdings, Inc. entered into a material definitive agreement on July 8, 2024. The filing does not specify the nature of the agreement or any
• Lixte Biotech Appoints New CMO, Adds Director — 8-K · Jul 11, 2024 Risk: medium
  Lixte Biotechnology Holdings, Inc. announced on July 9, 2024, the appointment of Dr. John B. McCarthy as Chief Medical Officer and the election of Dr. Alan L. R

Risk Profile

Risk Assessment: Of LIXT's 49 recent filings, 8 were flagged as high-risk, 26 as medium-risk, and 15 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Lixte Biotechnology Holdings, INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: $0
• Net Income: -$3.47M
• EPS: -$0.92
• Debt-to-Equity: N/A
• Cash Position: $2.89M
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Geordan Pursglove
• Dr. John B. "Jack" Greene
• Dr. John B. McCarthy
• David L. Ficksman, Esq.
• Anthony W. Basch, Esq.
• Bastiaan van der Baan
• Dr. Alan L. Rabinowitz

Industry Context

Lixte Biotechnology Holdings, Inc. operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically focusing on oncology. The sector is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Companies like Lixte aim to develop novel cancer therapies by targeting specific biological pathways, such as Protein Phosphatase 2A (PP2A).

Top Tags

biotechnology (9) · material-agreement (6) · Biotechnology (6) · financials (5) · 8-K (5) · material-definitive-agreement (4) · corporate-governance (4) · Pharmaceuticals (4) · delisting (4) · listing-standards (4)

Key Numbers

• Net Loss: $3.47M — Increased from $2.97M for the nine months ended September 30, 2024, indicating growing operational losses.
• Cash: $2.89M — Increased from $1.04M at December 31, 2024, primarily due to equity financings.
• Financing Proceeds: $6.47M — Net cash provided by financing activities for the nine months ended September 30, 2025, crucial for funding operations.
• R&D Costs: $202,801 — Decreased significantly from $691,402 for the nine months ended September 30, 2024.
• G&A Costs: $3.08M — Increased from $2.27M for the nine months ended September 30, 2024, indicating rising administrative expenses.
• Digital Asset Purchases: $2.64M — New investment in digital assets during the nine months ended September 30, 2025.
• Total Stockholders' Equity: $4.91M — Increased from $827,219 at December 31, 2024, helping regain Nasdaq compliance.
• Net Loss Per Share: $0.92 — Decreased from $1.32 for the nine months ended September 30, 2024, due to increased share count.
• Common Shares Outstanding: 5,704,200 — Increased from 2,249,290 at December 31, 2024, reflecting significant dilution.
• Contractual Commitments: $510,000 — Remaining financial commitments for clinical trials through December 31, 2027.
• Increase in 2020 Stock Incentive Plan: 2,750,000 shares — Proposed increase to the total shares available for issuance under the plan
• Total shares in 2020 Stock Incentive Plan: 3,500,000 shares — New total if the amendment is approved, up from an unspecified prior amount
• Common stock outstanding: 5,704,200 shares — Number of shares entitled to vote as of the October 14, 2025 record date
• Annual Meeting Date: December 8, 2025 — Date of the 2025 Annual Meeting of Stockholders
• Record Date: October 14, 2025 — Date for determining stockholders entitled to vote at the Annual Meeting

Frequently Asked Questions